Serina Therapeutics completed Cohort 1 dosing of SER-252, an apomorphine therapy designed to deliver continuous dopaminergic stimulation in advanced Parkinson's disease. The Phase 1b trial enrolled eight patients across US and Australia sites ahead of schedule, with safety review and dose-escalation decisions pending.
Key Points
- SER-252 uses POZ polymer platform for controlled, continuous dopamine delivery
- Cohort 1 complete with eight patients; five single-dose cohorts planned total
- Preclinical data support continuous stimulation without typical skin reactions
Longevity Analysis
Continuous dopaminergic stimulation addresses a core challenge in Parkinson's management: maintaining stable neural signaling and voluntary movement control over time. Current intermittent dosing regimens create fluctuations in motor function and compound the degenerative trajectory. A delivery system engineered to provide steady-state dopamine levels without the inflammatory burden of skin reactions could meaningfully extend functional autonomy in advanced disease. This approach recognizes that sustaining cellular communication patterns—rather than simply introducing more neurotransmitter—determines whether neurological resilience persists.
Original published by Longevity.Technology.